News

Medtronic, a global leader in medical device innovation, has officially launched the Neuroguard Integrated Embolic Protection (IEP) system, marking a major advancement in the treatment of carotid artery disease. This full market release follows a successful limited rollout and stems from a strategic partnership with Contego Medical, the original creator of the technology. The Neuroguard IEP system features a unique 3-in-1 design—combining a stent, post-dilation balloon, and embolic filter into a single device—aimed at improving patient outcomes and streamlining the stenting procedure.

 

Representing a breakthrough in carotid artery disease management, the Neuroguard IEP has shown encouraging results in the PERFORMANCE II study. Notably, the trial reported zero major strokes, neurological deaths, or stent-related complications, even among patients with heavily calcified lesions. By addressing critical challenges in carotid stenting, this next-generation solution enhances both safety and procedural efficiency in a high-risk patient population.

 

The rollout underscores Medtronic’s commitment to driving innovation through strategic collaborations, with Contego Medical playing a key role in bringing this technology to market. Looking ahead, the upcoming PERFORMANCE III trial will further explore the benefits of Neuroguard’s next-generation TCAR-IEP system, potentially solidifying its role in future standards of care.

 

With the full-scale release of the Neuroguard IEP system, Medtronic is poised to reshape the landscape of carotid artery disease treatment, offering clinicians a powerful tool to improve outcomes and reduce procedural risks. As anticipation builds around future clinical data, this launch reinforces Medtronic’s dedication to transforming cardiovascular care through forward-thinking innovation.

Source: Medtronic